Larimar Therapeutics (LRMR) Common Equity (2016 - 2020)
Historic Common Equity for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $102.6 million.
- Larimar Therapeutics' Common Equity rose 7141.12% to $102.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $102.6 million, marking a year-over-year increase of 7141.12%. This contributed to the annual value of -$694000.0 for FY2019, which is 10074.41% down from last year.
- Larimar Therapeutics' Common Equity amounted to $102.6 million in Q3 2020, which was up 7141.12% from $112.5 million recorded in Q2 2020.
- Larimar Therapeutics' Common Equity's 5-year high stood at $154.4 million during Q1 2016, with a 5-year trough of -$694000.0 in Q4 2019.
- In the last 5 years, Larimar Therapeutics' Common Equity had a median value of $93.3 million in 2018 and averaged $90.5 million.
- Its Common Equity has fluctuated over the past 5 years, first crashed by 10074.41% in 2019, then skyrocketed by 7141.12% in 2020.
- Quarter analysis of 5 years shows Larimar Therapeutics' Common Equity stood at $121.7 million in 2016, then crashed by 35.74% to $78.2 million in 2017, then rose by 19.25% to $93.3 million in 2018, then plummeted by 100.74% to -$694000.0 in 2019, then soared by 14889.77% to $102.6 million in 2020.
- Its Common Equity was $102.6 million in Q3 2020, compared to $112.5 million in Q2 2020 and $50.7 million in Q1 2020.